Programme Highlight

Session 1: HBV infection how to monitor and how to treat in 2014

1. Bitherapy in HBV infection: present and future in IFN-NUC association

2. Management of HBV during pregnancy

3. HBV therapy in iatrogenic immunosuppressed patients

4. Does the HBV therapy reduce the risk of hepatocellular carcinoma?

Session 2: HCV infection

1. Controlling the HCV epidemic through interruption of transmission

2. Some solved and unsolved problems in HCV therapy

3. IFN free therapy of HCV infection

4. New models of care for HCV patients

5. Universal access to antiviral medication – challenges for the hepatitis patient

6. Case studies: opportunities to achieve best practices in HCV patients

Session 3: NASH pathogenesis and treatment in 2014

1. Can we predict mortality and disease progression in NAFLD?

2. Cardiovascular and renal involvement in NASH

3. NASH and the risk of HCC

4. Current clinical trials and promising drugs in NASH/NAFLD

Session 4: Liver cirrhosis and its complications

1. Advances in HRS treatment

2. Is MARS efficient as liver support therapy?

3. Treatment of hepatic encephalopathy

4. Management of variceal upper digestive hemorrhage in 2014

Session 5: Liver cancer progress in diagnosis and treatment

1. Novel drivers and targeted therapies in HCC

2. Challenges for first-line therapies in intermediate and advanced HCC

3. Revisiting second-line treatments in HCC

4. Liver transplant for HCC

Session 6: Liver transplant in 2014

1. Living related liver transplant in Romania

2. Assessment of patients with metabolic syndrome before liver transplantation

3. The other side of the coin: increased incidence of transplantation of fatty livers

4. Critical care management of obese patients undergoing liver transplantation

5. Prevention of NAFLD/NASH recurrence and management of metabolic syndrome after liver transplantation in adults and adolescents